Derisking Clinical Trials
Our mission is to derisk Clinical Trials in order to encourage vital global drug development.
Our solutions are designed to provide downside risk protection for clinical trials by paying out in the event of failure.
Despite $55bn spent annually worldwide on Clinical Trials this is not enough to meet the demand for new drugs.
Attracting sufficient investment for much needed drug development is a long standing challenge as it is high risk, expensive and low return.
Innovatrix was established to change this by acting as a bridge between the Life Sciences and Risk Capital markets.
Our suite of solutions offer downside risk protection through Parametric (model driven) or traditional Indemnity based insurance products for any registered Clinical Trial irrespective of Therapeutic Area, Geography or Phase.
Parametric (model drive) insurance is increasingly a mainstream insurance product for both sophisticated companies and investors.
Our next generation parametric solution will offer robust resilience to life cycle variations in Life Sciences R&D.
Payouts triggered upon failure of early termination of a Clinical Trial due to missed pre agreed primary protocol endpoints.
Transparent
Clear and straightforward policy wording and terms
Affordable
Competitive when compared to other risk mitigation mechanisms
Customised
Tailored to client individual needs
Efficient
Claims payment made quickly
STEP 1
We design customised cover for our client based on predefined parameters and a pre agreed indemnity
Step 2
We monitor how the parameters evolve relative to the predetermined exposure framework
Step 3
If triggered, clients are notified and quickly indemnified
We're seeking views on our groundbreaking solution to shield the Life Sciences sector
from the failure of a clinical trial by reimbursing the expenses incurred in a specific failed
Clinical Trial phase.
By participating in our short survey you'll directly influence the development of our industry
changing product.
To access the survey click on this link Innovatrix Survey
Copyright © 2024 Innovatrix Capital Limited - All Rights Reserved.